دورية أكاديمية
أعرض في EDS

Downregulation of enhancer RNA AC003092.1 is associated with poor prognosis in kidney renal clear cell carcinoma.

التفاصيل البيبلوغرافية
العنوان: Downregulation of enhancer RNA AC003092.1 is associated with poor prognosis in kidney renal clear cell carcinoma.
المؤلفون: Li J; Department of Urology, School of Medicine, Wuhan Third Hospital, Wuhan University of Science and Technology, Wuhan, 430060, China., Gan J; Department of Urology, School of Medicine, Wuhan Third Hospital, Wuhan University of Science and Technology, Wuhan, 430060, China., Chen C; Department of Urology, School of Medicine, Wuhan Third Hospital, Wuhan University of Science and Technology, Wuhan, 430060, China., Yuan Y; Department of Urology, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, 430060, China., Xiong X; Department of Urology, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, 430060, China., Li L; Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, 430060, China. 26061047@qq.com., Luo P; Department of Urology, School of Medicine, Wuhan Third Hospital, Wuhan University of Science and Technology, Wuhan, 430060, China. pluo@whu.edu.cn., Zhang W; Department of Urology, Wuhan Third Hospital, Wuhan, 430060, China. 1006847164@qq.com.
المصدر: Scientific reports [Sci Rep] 2024 Jun 12; Vol. 14 (1), pp. 13475. Date of Electronic Publication: 2024 Jun 12.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Carcinoma, Renal Cell*/genetics , Carcinoma, Renal Cell*/pathology , Carcinoma, Renal Cell*/metabolism , Kidney Neoplasms*/genetics , Kidney Neoplasms*/pathology , Kidney Neoplasms*/metabolism , Gene Expression Regulation, Neoplastic* , Cell Proliferation*/genetics, Humans ; Prognosis ; Cell Line, Tumor ; Down-Regulation/genetics ; Cell Movement/genetics ; Female ; Male ; RNA, Long Noncoding/genetics ; RNA, Long Noncoding/metabolism ; Computational Biology/methods ; Middle Aged ; Enhancer RNAs
مستخلص: Kidney renal clear cell carcinoma (KIRC) is the most common histological type of renal cancer, enhancer RNA plays a significant role in tumor growth, however, it has been less studied in renal cancer. The aim of this study was to investigate the role of eRNA AC003092.1 in KIRC. Clinical and RNA expression data were downloaded from a TCGA database, and performed bioinformatics analysis, including expression level analysis, survival analysis, clinical correlation analysis, immune correlation analysis. We further confirmed the expression level of AC003092.1 between normal and tumor cell, predicted the biological role of AC003092.1 in KIRC, and performed cell proliferation and wound healing assays, followed by GSEA enrichment analysis and western blot to detect the proteins of the enriched pathway. Bioinformatics results showed that AC003092.1 expression was elevated in tumor tissues, and knockdown of AC003092.1 expression inhibited cell proliferation and migration. GSEA and western blot results showed that knockdown AC003092.1 expression alleviated the extracellular matrix (ECM) process in KIRC cell lines. Our study provides evidence that AC003092.1 play an important role in KIRC, and AC003092.1 may promote tumor cell progression by affecting the ECM process during tumor development.
(© 2024. The Author(s).)
References: Front Genet. 2021 Mar 18;12:633812. (PMID: 33815468)
RNA Biol. 2020 Nov;17(11):1550-1559. (PMID: 31916476)
Nature. 2014 Mar 27;507(7493):455-461. (PMID: 24670763)
Bioessays. 2015 Mar;37(3):314-23. (PMID: 25450156)
Annu Rev Genet. 2012;46:1-19. (PMID: 22905871)
Int J Mol Sci. 2022 Sep 30;23(19):. (PMID: 36232885)
Methods Mol Biol. 2015;1312:17-30. (PMID: 26043986)
Nat Commun. 2019 Oct 8;10(1):4562. (PMID: 31594934)
Nat Commun. 2022 Sep 30;13(1):5747. (PMID: 36180422)
Cancer Sci. 2022 Apr;113(4):1220-1234. (PMID: 35189004)
Nat Immunol. 2012 Dec;13(12):1196-204. (PMID: 23064439)
Mol Cell. 2013 Feb 7;49(3):524-35. (PMID: 23273978)
Nature. 1981 Mar 26;290(5804):304-10. (PMID: 6259538)
Trends Cell Biol. 2022 Jan;32(1):30-44. (PMID: 34304958)
Cell. 2018 Apr 5;173(2):386-399.e12. (PMID: 29625054)
SLAS Technol. 2018 Dec;23(6):493-506. (PMID: 29945466)
Nat Rev Dis Primers. 2017 Mar 09;3:17009. (PMID: 28276433)
J Clin Oncol. 2016 Jun 20;34(18):2157-64. (PMID: 27138577)
Mol Cancer Ther. 2018 Jul;17(7):1355-1364. (PMID: 29967214)
Proc Natl Acad Sci U S A. 2014 May 20;111(20):7319-24. (PMID: 24778216)
J Cell Biochem. 2019 Mar;120(3):2782-2790. (PMID: 30321449)
Cancer Res. 2017 Aug 1;77(15):3965-3981. (PMID: 28701486)
Nature. 2013 Jun 27;498(7455):511-5. (PMID: 23728303)
Nat Rev Cancer. 2016 Aug 23;16(9):582-98. (PMID: 27550820)
Cancer Res. 2021 Aug 15;81(16):4174-4182. (PMID: 34016622)
Cell Death Dis. 2018 Nov 15;9(12):1139. (PMID: 30442884)
Cold Spring Harb Perspect Med. 2016 May 02;6(5):. (PMID: 27048304)
Cell. 1993 Nov 19;75(4):805-16. (PMID: 8242751)
Nature. 2012 Sep 6;489(7414):109-13. (PMID: 22955621)
Proc Natl Acad Sci U S A. 1980 Dec;77(12):7102-6. (PMID: 6938957)
معلومات مُعتمدة: 2020020601012209 Hubei leading talent program in medicine, Wuhan application foundation and frontier project; WX21B04 the Wuhan city surface project
المشرفين على المادة: 0 (RNA, Long Noncoding)
0 (Enhancer RNAs)
تواريخ الأحداث: Date Created: 20240612 Date Completed: 20240612 Latest Revision: 20240615
رمز التحديث: 20240615
مُعرف محوري في PubMed: PMC11169679
DOI: 10.1038/s41598-024-64431-8
PMID: 38866983
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-64431-8